Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences has announced the acquisition of ACell for $300 million, with additional payments of up to $100 million based on revenue milestones. This strategic move reinforces Integra's regenerative medicine capabilities, particularly in tissue technologies. ACell's proprietary products, including MatriStem UBM™, will be integrated into Integra's existing offerings, enhancing its portfolio. In 2019, ACell reported revenues of $100.8 million, showing 13% growth. The acquisition is expected to be accretive to revenue growth and adjusted gross margins, with a neutral impact on adjusted EBITDA margin and earnings per share in the first year.
Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2020 revenues of $370.2 million, down 2.3% year-over-year but up 43.1% sequentially. GAAP earnings per diluted share were $0.38, reversing a loss from the prior year. Adjusted net income increased to $67.7 million, or $0.80 per share. The company maintained a strong financial position with $396 million in cash. However, full-year 2020 guidance remains withdrawn due to COVID-19 uncertainties impacting surgical volumes. Management expects further revenue improvement in Q4, barring significant pandemic setbacks.
Integra LifeSciences (NASDAQ: IART) reported preliminary third quarter revenue of $368 to $370 million, indicating a 2.7% decline year-over-year. This organic revenue decline of 1.8% is a significant recovery from the 32.6% decrease in the second quarter. The results surpassed the company's earlier outlook and showed broad-based sales improvements across its major franchises. Full financial results will be released on October 28, 2020, along with a conference call for further insights.
Integra LifeSciences (NASDAQ: IART) has announced its participation in two upcoming investor conferences in September 2020. Carrie Anderson, the CFO, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 10 at 9:20 AM ET, followed by CEO Peter Arduini at the Morgan Stanley Virtual Global Healthcare Conference on September 14 at 10:30 AM ET. Both presentations will be webcasted on the company’s investor relations website. Integra is a leader in regenerative technologies and aims to enhance patient care through its comprehensive product portfolio.
Integra LifeSciences Holdings Corporation (IART) reported second-quarter revenues of $258.7 million, down 32.6% year-over-year, mainly due to COVID-19's impact on surgical procedures. The company reported a GAAP loss per diluted share of ($0.00) compared to $0.34 in Q2 2019. Adjusted earnings per diluted share fell to $0.33 from $0.73. Gross margins also declined, with GAAP margins at 59.2%. Despite challenges, revenue showed sequential improvement, and the company ended the quarter with $361 million in cash. Full-year guidance remains withdrawn due to ongoing uncertainties.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) has received FDA clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System, specifically for neurosurgery. This system is now indicated for the safe and effective resection of tumors, including malignant and benign types, marking a significant advancement in neurosurgical technology. The CUSA system has over 40 years of clinical use and is noted for its ability to enhance surgical outcomes. The launch aligns with Glioblastoma Awareness Day, highlighting the importance of this technology in treating aggressive brain tumors.
Integra LifeSciences (NASDAQ: IART) announced preliminary second quarter 2020 revenue results, estimating revenues between $254 million and $256 million, reflecting a 34% decline from 2019. Despite improving monthly sales due to lifted COVID-19 restrictions, June sales were down approximately 15% from the previous year's second quarter. The company will share full financial results on August 10, 2020, and acknowledges ongoing uncertainty regarding future revenue impacts.
Integra LifeSciences (IART) has announced a leadership change, promoting Michael McBreen to executive vice president and president of Codman Specialty Surgical, effective June 8, 2020. McBreen replaces Dan Reuvers, who is leaving to become CEO of Tactile Systems Technology. McBreen has a strong background with Codman Neurosurgery, having joined Integra through its acquisition from Johnson & Johnson in 2017. Peter Arduini, CEO, praised McBreen's leadership while acknowledging Reuvers' contributions to the company's success in neurosurgery.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in two investor conferences in May 2020. Glenn Coleman, COO, will present at the BofA Securities Virtual Health Care Conference on May 12 at 11:40 am ET. Carrie Anderson, CFO, will present at the UBS Virtual Global Healthcare Conference on May 20, also at 11:40 am ET, with a webcast available on the company’s investor relations site. The company is a leader in regenerative technologies and emphasizes its commitment to providing high-quality solutions for healthcare professionals.
Integra LifeSciences reported Q1 2020 revenues of $354.3 million, down (1.5)% year-over-year, attributed to COVID-19 impacts. GAAP earnings per diluted share fell to $0.11 from $0.38 in Q1 2019. Adjusted earnings were $0.48, compared to $0.65 previously. The company estimates a revenue hit of $20-$25 million due to deferred surgical procedures. Gross margin decreased to 62.3%, and adjusted EBITDA was $75.7 million. Full-year guidance remains withdrawn due to uncertainties from the pandemic.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
